PCV70 HEALTH CARE COST FOR PATIENTS WITH CHRONIC HEART FAILURE AND IRON DEFICIENCY / ANEMIA BEFORE AND AFTER TREATMENT WITH FERRIC CARBOXYMALTOSE. admin8. November 2025
Lower cardiorenal risk with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study. admin8. November 2025
Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort study. admin8. November 2025
How representative of a general type 2 diabetes population are patients included in cardiovascular outcome trials with SGLT2 inhibitors? A large European observational study. admin8. November 2025
Das kardiorenale Syndrom ist die häufigste erste kardiovaskuläre Manifestation beim Typ-2-Diabetes und mit erhöhter Mortalität assoziiert: eine große multinationale Beobachtungsstudie admin8. November 2025
Clinical and economic burden of hypertrophic obstructive cardiomyopathy in Germany. admin8. November 2025
Cardiorenal Risk with SGLT2i versus DPP4i in T2D Patients without Established Cardiovascular- and Renal Diseases: A Large Multinational Observational Study admin8. November 2025
Cardiorenal Risk with Sodium‐Glucose Cotransporter‐2 Inhibitors versus Dipeptidyl Peptidase‐4 Inhibitors in Type 2 Diabetes Patients without Cardiovascular and Renal Diseases: A large multinational observational study; admin8. November 2025
Cardiorenal disease is the most common first CV manifestation in type 2 diabetes and associated with increased mortality: a large multinational observational study. admin8. November 2025
Cardiorenal disease is the most common first CV manifestation in type 2 diabetes and associated with increased mortality: a large multinational observational study. admin8. November 2025
